Stem Cell Therapy in Duchenne Muscular Dystrophy

Neurogen Brain and Spine Institute

Status and phase: Withdrawn; Phase 1

Conditions: Duchenne Muscular Dystrophy

Treatments: Biological: Stem Cell

Study type: Interventional

Funder types: Other

Identifiers

NCT02241434

NGBSI-13

Details and patient eligibility

About

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

Sex: All

Ages: 3 to 25 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age group of 3-25 years
• Duchenne muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion criteria

• presence of respiratory distress
• presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
• malignancies
• acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
• pregnancy or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Stem Cell

Experimental group

Description:

bone marrow mononuclear cell transplantation

Treatment:

Biological: Stem Cell